Short Interest Worth Mentioning: Could Acura Pharmaceuticals Incorporated (NASDAQ:ACUR) Skyrocket? The Stock Has Too Many Sellers

November 23, 2016 - By Ellis Scott   ·   0 Comments

Short Interest Worth Mentioning: Could Acura Pharmaceuticals Incorporated (NASDAQ:ACUR) Skyrocket? The Stock Has Too Many Sellers

The stock of Acura Pharmaceuticals Incorporated (NASDAQ:ACUR) registered an increase of 20.99% in short interest. ACUR’s total short interest was 80,700 shares in November as published by FINRA. Its up 20.99% from 66,700 shares, reported previously. With 36,900 shares average volume, it will take short sellers 2 days to cover their ACUR’s short positions. The short interest to Acura Pharmaceuticals Incorporated’s float is 1.4%. The stock last traded at $0.99 per share. It is down 70.62% since April 21, 2016 and is downtrending. It has underperformed by 75.95% the S&P500.

Acura Pharmaceuticals, Inc. is a pharmaceutical company. The company has a market cap of $11.63 million. The Firm is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. It currently has negative earnings. The Firm has discovered and developed three platform technologies, which can be used to develop multiple products.

ACUR Company Profile

Acura Pharmaceuticals, Inc., incorporated on April 10, 1935, is a pharmaceutical company. The Firm is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Firm has discovered and developed three proprietary platform technologies, which can be used to develop multiple products.

Another recent and important Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) news was published by Quotes.Wsj.com which published an article titled: “News Acura Pharmaceuticals Inc.ACUR” on February 13, 2011.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Ellis Scott


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>